NGS-Based HLA Genotyping: Omixon and CHOP Collaborate

Omixon is very proud to announce an exclusive licensing agreement with The Children’s Hospital of Philadelphia (CHOP) to commercialize a new Next Generation Sequencing (NGS) HLA genotyping assay, for use on the Illumina® MiSeq sequencing platform. The Illumina-specific HLA genotyping protocol was developed by Professor Dimitri Monos, Director of...

 

Read more

Omixon Raises Capital, Launches US Office

Omixon has opened its first offices in Cambridge, MA to support the growing demand from customers for their HLA genotyping software, Omixon Target™ HLA Typing. The US office will be responsible for all in-market activities relating to sales, support and training for Omixon’s products with an additional focus on...

 

Read more

Omixon Awarded 100k Genome Research Grant

Winners from a £10 million competition to help businesses develop new technology to map and analyse genes have been announced on 2 May. Eight companies were successful and will share a total of £1.casinos online6 million. The winners will use this funding from phase 1 of the competition to...

 

Read more

Omixon at This Year’s Immuno B4B-Connection Conference!

Agnes Pasztor, Omixon’s Customer Support Manager and our French distributor WiraTech Europe‘s CEO Sami Djoulah, attended this year’s Immuno B4B-Connection in Charleroi Biopark, Belgium. At least 120 people from different companies participated in the 2 day conference, consisting of various presentations and introductions to the many different companies and their field of interest....

 

Read more

8th East-West Immunogenetics Conference in Vienna, February 13-14, 2014

Vienna was home to the 8th East-West Immunogenetics Conference attended by scientists and transplantation specialists mainly from Europe. Visit the EWIC website: http://www.ewic2014.net/index.php?id=1376 The conference covered a range of topics from disease associations to technical aspects of HLA typing. In this summary, I only make a few remarks on...

 

Read more